Comment on ‘Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety’

Koren, Andrew; Karas, Andreas; Echols, Roger

doi:10.1007/s40261-021-01043-4

Cited by 3 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The other component, vaborbactam, is a β-lactamase inhibitor with no antibacterial activity that can protect meropenem from degradation by some serine-lactamases, such as Klebsiella pneumoniae carbapenemase [ 147 ]. Vabomere is mainly used in the treatment of cUTIs [ 148 ].…”

Section: Antibiotics That Interfere With Bacterial Cell Wall Synthesismentioning

confidence: 99%

A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects

et al. 2023

View full text Add to dashboard Cite

Due to the overuse of antibiotics, bacterial resistance has markedly increased to become a global problem and a major threat to human health. Fortunately, in recent years, various new antibiotics have been developed through both improvements to traditional antibiotics and the discovery of antibiotics with novel mechanisms with the aim of addressing the decrease in the efficacy of traditional antibiotics. This manuscript reviews the antibiotics that have been approved for marketing in the last 20 years with an emphasis on the antibacterial properties, mechanisms, structure–activity relationships (SARs), and clinical safety of these antibiotics. Furthermore, the current deficiencies, opportunities for improvement, and prospects of antibiotics are thoroughly discussed to provide new insights for the design and development of safer and more potent antibiotics.

show abstract

Section: Antibiotics That Interfere With Bacterial Cell Wall Synthesismentioning

confidence: 99%

A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Another randomised, open-label section three research (CREDIBLECR, NCT02714595) started in 2017 to offer proof of cefiderocol's efficacy in sufferers with carbapenem-resistant GNB infections (healthcarerelated pneumonia [HCAP], cUTI, VAP, HAP, and BSI). 68 Cefiderocol is as compared to the quality to be had the remedy for carbapenem-resistant GNB, which incorporates up to a few antibacterial sellers and is both polymyxin-primarily based totally or non-polymyxin-primarily based. 69 Despite the absence of clear findings from phase 3 studies, we think Cefiderocol is among the most potential future therapy choices for carbapenem-resistant Gram-negative MDR bacteria such CRPA, CRE, and CRAB infections.…”

Section: Cefiderocolmentioning

confidence: 99%

Treatment of MDR Gram-Negative Bacteria Infections: Ongoing and Prospective

Sharma¹,

Rizvan²,

Ahmad³

et al. 2022

J. Pure Appl. Microbiol.

View full text Add to dashboard Cite

Antimicrobial resistance is a serious public health concern across the world. Gram-negative resistance has propagated over the globe via various methods, the most challenging of which include extended-spectrum β-lactamases, carbapenemases, and AmpC enzymes. Gram-negative bacterial infections are difficult to treat in critically extremely sick persons. Resistance to different antibiotic treatments nearly always lowers the probability of proper empirical coverage, sometimes resulting in severe outcomes. Multidrug resistance can be combated with varying degrees of success using a combination of older drugs with high toxicity levels and novel therapeutics. The current therapies for multidrug-resistant Gram-negative bacteria are discussed in this review, which includes innovative medications, older pharmaceuticals, creative combinations of the two, and therapeutic targets.

show abstract

Response to “Comment on: Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety”

Lee

2021

Clin Drug Investig

View full text Add to dashboard Cite

Comment on ‘Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety’

Cited by 3 publications

References 2 publications

A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects

A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects

Treatment of MDR Gram-Negative Bacteria Infections: Ongoing and Prospective

Response to “Comment on: Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety”

Contact Info

Product

Resources

About